Biocon Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: February 24, 2025, 2:06 pm

Market Cap	38,605 Cr.
Current Price	321
High / Low	405/244
Stock P/E	46.9
Book Value	175
Dividend Yield	0.16 %
ROCE	5.96 %
ROE	5.25 %
Face Value	5.00
PEG Ratio	4.74

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Biocon Ltd

Competitors of Biocon Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.27 Cr.	3.80	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	50.4 Cr.	67.9	94.9/30.8	17.1	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	41.3 Cr.	28.2	29.0/8.74	42.2	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	68.2 Cr.	90.5	155/81.2	11.0	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,201.67 Cr	1,062.38		42.63	185.19	0.37%	16.18%	16.43%	6.27

All Competitor Stocks of Biocon Ltd

Quarterly Result

Metric	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Sales	1,857	1,842	1,761	1,840	2,174	2,409	2,140	2,320	2,941	3,774	3,423	3,462	3,954
Expenses	1,459	1,476	1,427	1,445	1,733	1,870	1,783	1,877	2,352	2,817	2,741	2,745	3,051
Operating Profit	399	366	333	395	441	539	356	442	589	957	681	717	903
OPM %	21%	20%	19%	21%	20%	22%	17%	19%	20%	25%	20%	21%	23%
Other Income	28	218	47	35	48	26	78	48	-193	152	94	134	587
Interest	5	34	20	22	15	10	20	30	120	249	233	248	267
Depreciation	186	184	195	202	206	212	218	231	301	364	358	389	414
Profit before tax	236	366	166	206	269	342	197	229	-26	497	184	214	808
Tax %	21%	19%	35%	22%	18%	17%	15%	64%	19%	17%	19%	19%	7%
Net Profit	187	296	108	160	220	284	167	82	-21	414	149	173	753
EPS in Rs	1.40	2.11	0.70	1.15	1.56	1.99	1.20	0.39	-0.35	2.61	0.84	1.05	5.50

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Metric	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Sales	2,086	2,485	2,877	3,090	3,347	3,891	4,123	5,514	6,300	7,143	8,184	11,174	14,612
Expenses	1,569	1,942	2,190	2,394	2,957	2,912	3,294	4,121	4,725	5,562	6,391	8,762	11,354
Operating Profit	517	543	687	696	390	980	829	1,394	1,575	1,581	1,793	2,412	3,258
OPM %	25%	22%	24%	23%	12%	25%	20%	25%	25%	22%	22%	22%	22%
Other Income	62	255	56	158	639	173	228	340	228	260	72	18	966
Interest	12	8	2	9	29	26	62	71	65	58	68	419	996
Depreciation	174	179	204	221	249	277	385	448	552	715	814	1,113	1,526
Profit before tax	392	610	538	624	751	850	610	1,215	1,186	1,068	983	897	1,703
Tax %	14%	16%	20%	15%	19%	19%	26%	17%	27%	21%	22%	28%
Net Profit	338	513	431	528	609	688	453	1,003	871	846	772	643	1,489
EPS in Rs	2.82	4.24	3.45	4.14	4.59	5.10	3.10	7.54	6.24	6.17	5.40	3.85	10.00
Dividend Payout %	30%	29%	24%	20%	18%	10%	16%	7%	0%	0%	9%	39%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2012-2013	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023
YoY Net Profit Growth (%)	51.78%	-15.98%	22.51%	15.34%	12.97%	-34.16%	121.41%	-13.16%	-2.87%	-8.75%	-16.71%
Change in YoY Net Profit Growth (%)	0.00%	-67.76%	38.49%	-7.16%	-2.37%	-47.13%	155.57%	-134.57%	10.29%	-5.88%	-7.96%

Biocon Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:	18%
5 Years:	22%
3 Years:	27%
TTM:	1%

Compounded Profit Growth
10 Years:	9%
5 Years:	6%
3 Years:	11%
TTM:	-31%

Stock Price CAGR
10 Years:	16%
5 Years:	1%
3 Years:	-7%
1 Year:	18%

Return on Equity
10 Years:	8%
5 Years:	7%
3 Years:	6%
Last Year:	5%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:35 am

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	100	100	100	100	100	300	300	600	600	600	600	600	600
Reserves	2,595	2,927	3,171	3,934	4,738	4,881	5,798	6,106	7,027	7,832	17,267	19,183	20,393
Borrowings	267	864	1,117	2,478	2,302	2,264	2,422	2,715	4,481	5,147	18,019	16,277	16,771
Other Liabilities	1,454	1,860	1,988	1,947	2,254	2,545	3,672	4,993	6,382	6,763	15,856	19,693	19,364
Total Liabilities	4,416	5,751	6,375	8,458	9,394	9,990	12,192	14,414	18,490	20,342	51,742	55,753	57,128
Fixed Assets	1,510	1,525	1,630	1,748	3,626	3,700	4,471	5,971	6,364	6,569	29,468	30,644	34,792
CWIP	312	1,206	1,677	2,240	839	1,303	1,899	2,196	2,800	4,110	7,317	7,993	4,354
Investments	587	765	230	902	1,253	675	1,012	966	1,952	1,588	2,069	1,000	1,809
Other Assets	2,007	2,255	2,839	3,569	3,676	4,312	4,811	5,281	7,374	8,074	12,888	16,117	16,174
Total Assets	4,416	5,751	6,375	8,458	9,394	9,990	12,192	14,414	18,490	20,342	51,742	55,753	57,128

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	471	561	211	371	640	662	1,155	1,283	1,160	1,177	1,852	2,954
Cash from Investing Activity +	-358	-904	-491	-1,138	-510	-684	-703	-1,505	-3,651	-1,662	-14,260	-1,002
Cash from Financing Activity +	-9	426	186	1,068	-178	-240	-242	388	2,564	242	13,049	-2,333
Net Cash Flow	105	83	-94	300	-47	-261	210	165	72	-243	641	-380

Free Cash Flow

Month	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Free Cash Flow	517.00	276.00	-177.00	695.00	388.00	978.00	827.00	-1.00	-1.00	-3.00	-4.00	-16.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	75	76	91	78	83	94	86	71	77	92	117	154
Inventory Days	139	116	132	153	160	161	199	263	304	309	423	368
Days Payable	121	107	125	172	187	224	231	243	246	216	383	467
Cash Conversion Cycle	93	85	98	59	57	31	53	91	134	184	157	55
Working Capital Days	21	-0	12	31	34	18	15	8	80	112	85	2
ROCE %	15%	15%	12%	9%	12%	8%	13%	12%	10%	9%	6%	6%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%
FIIs	15.74%	16.00%	15.62%	16.31%	15.79%	14.42%	10.20%	9.52%	7.97%	6.55%	5.63%	5.90%
DIIs	7.44%	7.37%	8.36%	7.72%	7.76%	8.63%	11.89%	12.59%	14.08%	14.51%	13.69%	14.29%
Public	15.46%	15.34%	14.76%	14.60%	15.17%	15.74%	16.70%	16.77%	16.92%	17.96%	19.74%	18.90%
Others	0.72%	0.65%	0.63%	0.73%	0.63%	0.58%	0.55%	0.49%	0.39%	0.33%	0.32%	0.28%
No. of Shareholders	3,63,447	3,64,502	3,47,911	3,41,016	3,69,816	3,91,382	4,11,086	4,12,441	4,15,046	4,34,339	4,70,261	4,43,513

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
SBI Contra Fund	16,770,774	1.83	463.71	4,100,000	2025-02-22	309.04%
Mirae Asset Large Cap Fund	10,709,389	0.79	296.11	4,100,000	2025-02-22	161.2%
SBI Balanced Advantage Fund	10,021,205	0.99	277.09	4,100,000	2025-02-22	144.42%
Quant Flexi Cap Fund	5,611,098	3.73	155.15	4,100,000	2025-02-22	36.86%
Quant Mid Cap Fund	4,100,000	2.09	113.37	4,100,000	2025-02-22	0%
Kotak Equity Arbitrage Fund - Regular Plan	4,025,000	0.28	111.29	4,100,000	2025-02-22	-1.83%
SBI Arbitrage Opportunities Fund	3,397,500	0.34	93.94	4,100,000	2025-02-22	-17.13%
ICICI Prudential India Opportunities Fund	3,114,146	0.5	86.11	4,100,000	2025-02-22	-24.05%
Sundaram Mid Cap Fund	3,080,023	0.83	85.16	4,100,000	2025-02-22	-24.88%
Sundaram Mid Cap Fund - Institutional Plan	3,080,023	0.83	85.16	4,100,000	2025-02-22	-24.88%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	5.00	5.00	5.00	5.00	5.00
Basic EPS (Rs.)	8.55	3.88	5.44	6.24	6.32
Diluted EPS (Rs.)	8.54	3.87	5.42	6.19	6.30
Cash EPS (Rs.)	24.58	16.02	14.93	13.59	11.86
Book Value[Excl.RevalReserv]/Share (Rs.)	210.51	187.31	78.87	70.09	61.52
Book Value[Incl.RevalReserv]/Share (Rs.)	210.52	187.31	78.88	70.10	61.53
Revenue From Operations / Share (Rs.)	122.90	93.07	68.17	59.22	52.50
PBDIT / Share (Rs.)	34.68	24.05	18.18	15.89	14.70
PBIT / Share (Rs.)	21.62	14.78	11.40	9.93	10.10
PBT / Share (Rs.)	13.40	8.86	9.91	9.56	10.12
Net Profit / Share (Rs.)	11.51	6.75	8.15	7.63	7.26
NP After MI And SOA / Share (Rs.)	8.52	3.85	5.40	6.17	6.24
PBDIT Margin (%)	28.22	25.84	26.67	26.83	28.00
PBIT Margin (%)	17.58	15.88	16.72	16.77	19.24
PBT Margin (%)	10.90	9.52	14.54	16.14	19.28
Net Profit Margin (%)	9.36	7.24	11.95	12.88	13.82
NP After MI And SOA Margin (%)	6.92	4.14	7.92	10.42	11.87
Return on Networth / Equity (%)	5.16	2.58	7.69	9.83	11.15
Return on Capital Employeed (%)	6.37	4.07	8.26	8.32	11.61
Return On Assets (%)	1.82	0.88	3.17	3.99	5.18
Long Term Debt / Equity (X)	0.65	0.85	0.47	0.39	0.18
Total Debt / Equity (X)	0.79	0.99	0.58	0.47	0.28
Asset Turnover Ratio (%)	0.27	0.30	0.12	0.17	0.19
Current Ratio (X)	0.98	1.45	2.19	1.81	1.33
Quick Ratio (X)	0.66	0.95	1.59	1.36	0.97
Inventory Turnover Ratio (X)	1.10	0.97	0.75	0.81	1.10
Dividend Payout Ratio (NP) (%)	17.61	12.96	0.00	0.00	8.42
Dividend Payout Ratio (CP) (%)	6.95	3.80	0.00	0.00	4.84
Earning Retention Ratio (%)	82.39	87.04	0.00	0.00	91.58
Cash Earning Retention Ratio (%)	93.05	96.20	0.00	0.00	95.16
Interest Coverage Ratio (X)	4.27	6.89	32.29	33.05	27.19
Interest Coverage Ratio (Post Tax) (X)	2.43	3.63	17.12	16.82	13.82
Enterprise Value (Cr.)	50669.85	44766.88	44360.07	51477.10	34040.50
EV / Net Operating Revenue (X)	3.43	4.01	5.42	7.24	5.40
EV / EBITDA (X)	12.17	15.50	20.32	26.99	19.29
MarketCap / Net Operating Revenue (X)	2.15	2.22	4.91	6.90	5.15
Retention Ratios (%)	82.38	87.03	0.00	0.00	91.57
Price / BV (X)	1.60	1.39	4.76	6.51	4.84
Price / Net Operating Revenue (X)	2.15	2.22	4.91	6.90	5.15
EarningsYield	0.03	0.01	0.01	0.01	0.02

After reviewing the key financial ratios for Biocon Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 24, the value is 8.55. This value is within the healthy range. It has increased from 3.88 (Mar 23) to 8.55, marking an increase of 4.67.
For Diluted EPS (Rs.), as of Mar 24, the value is 8.54. This value is within the healthy range. It has increased from 3.87 (Mar 23) to 8.54, marking an increase of 4.67.
For Cash EPS (Rs.), as of Mar 24, the value is 24.58. This value is within the healthy range. It has increased from 16.02 (Mar 23) to 24.58, marking an increase of 8.56.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 210.51. It has increased from 187.31 (Mar 23) to 210.51, marking an increase of 23.20.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 210.52. It has increased from 187.31 (Mar 23) to 210.52, marking an increase of 23.21.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 122.90. It has increased from 93.07 (Mar 23) to 122.90, marking an increase of 29.83.
For PBDIT / Share (Rs.), as of Mar 24, the value is 34.68. This value is within the healthy range. It has increased from 24.05 (Mar 23) to 34.68, marking an increase of 10.63.
For PBIT / Share (Rs.), as of Mar 24, the value is 21.62. This value is within the healthy range. It has increased from 14.78 (Mar 23) to 21.62, marking an increase of 6.84.
For PBT / Share (Rs.), as of Mar 24, the value is 13.40. This value is within the healthy range. It has increased from 8.86 (Mar 23) to 13.40, marking an increase of 4.54.
For Net Profit / Share (Rs.), as of Mar 24, the value is 11.51. This value is within the healthy range. It has increased from 6.75 (Mar 23) to 11.51, marking an increase of 4.76.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 8.52. This value is within the healthy range. It has increased from 3.85 (Mar 23) to 8.52, marking an increase of 4.67.
For PBDIT Margin (%), as of Mar 24, the value is 28.22. This value is within the healthy range. It has increased from 25.84 (Mar 23) to 28.22, marking an increase of 2.38.
For PBIT Margin (%), as of Mar 24, the value is 17.58. This value is within the healthy range. It has increased from 15.88 (Mar 23) to 17.58, marking an increase of 1.70.
For PBT Margin (%), as of Mar 24, the value is 10.90. This value is within the healthy range. It has increased from 9.52 (Mar 23) to 10.90, marking an increase of 1.38.
For Net Profit Margin (%), as of Mar 24, the value is 9.36. This value is within the healthy range. It has increased from 7.24 (Mar 23) to 9.36, marking an increase of 2.12.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 6.92. This value is below the healthy minimum of 8. It has increased from 4.14 (Mar 23) to 6.92, marking an increase of 2.78.
For Return on Networth / Equity (%), as of Mar 24, the value is 5.16. This value is below the healthy minimum of 15. It has increased from 2.58 (Mar 23) to 5.16, marking an increase of 2.58.
For Return on Capital Employeed (%), as of Mar 24, the value is 6.37. This value is below the healthy minimum of 10. It has increased from 4.07 (Mar 23) to 6.37, marking an increase of 2.30.
For Return On Assets (%), as of Mar 24, the value is 1.82. This value is below the healthy minimum of 5. It has increased from 0.88 (Mar 23) to 1.82, marking an increase of 0.94.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.65. This value is within the healthy range. It has decreased from 0.85 (Mar 23) to 0.65, marking a decrease of 0.20.
For Total Debt / Equity (X), as of Mar 24, the value is 0.79. This value is within the healthy range. It has decreased from 0.99 (Mar 23) to 0.79, marking a decrease of 0.20.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.27. It has decreased from 0.30 (Mar 23) to 0.27, marking a decrease of 0.03.
For Current Ratio (X), as of Mar 24, the value is 0.98. This value is below the healthy minimum of 1.5. It has decreased from 1.45 (Mar 23) to 0.98, marking a decrease of 0.47.
For Quick Ratio (X), as of Mar 24, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.95 (Mar 23) to 0.66, marking a decrease of 0.29.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.10. This value is below the healthy minimum of 4. It has increased from 0.97 (Mar 23) to 1.10, marking an increase of 0.13.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 17.61. This value is below the healthy minimum of 20. It has increased from 12.96 (Mar 23) to 17.61, marking an increase of 4.65.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 6.95. This value is below the healthy minimum of 20. It has increased from 3.80 (Mar 23) to 6.95, marking an increase of 3.15.
For Earning Retention Ratio (%), as of Mar 24, the value is 82.39. This value exceeds the healthy maximum of 70. It has decreased from 87.04 (Mar 23) to 82.39, marking a decrease of 4.65.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 93.05. This value exceeds the healthy maximum of 70. It has decreased from 96.20 (Mar 23) to 93.05, marking a decrease of 3.15.
For Interest Coverage Ratio (X), as of Mar 24, the value is 4.27. This value is within the healthy range. It has decreased from 6.89 (Mar 23) to 4.27, marking a decrease of 2.62.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.43. This value is below the healthy minimum of 3. It has decreased from 3.63 (Mar 23) to 2.43, marking a decrease of 1.20.
For Enterprise Value (Cr.), as of Mar 24, the value is 50,669.85. It has increased from 44,766.88 (Mar 23) to 50,669.85, marking an increase of 5,902.97.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 23) to 3.43, marking a decrease of 0.58.
For EV / EBITDA (X), as of Mar 24, the value is 12.17. This value is within the healthy range. It has decreased from 15.50 (Mar 23) to 12.17, marking a decrease of 3.33.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has decreased from 2.22 (Mar 23) to 2.15, marking a decrease of 0.07.
For Retention Ratios (%), as of Mar 24, the value is 82.38. This value exceeds the healthy maximum of 70. It has decreased from 87.03 (Mar 23) to 82.38, marking a decrease of 4.65.
For Price / BV (X), as of Mar 24, the value is 1.60. This value is within the healthy range. It has increased from 1.39 (Mar 23) to 1.60, marking an increase of 0.21.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has decreased from 2.22 (Mar 23) to 2.15, marking a decrease of 0.07.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 23) to 0.03, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation. If you have any questions or need more detailed insights, please feel free to reach out.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Biocon Ltd as of February 24, 2025 is: ₹345.27

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 24, 2025, Biocon Ltd is Undervalued by 7.56% compared to the current share price ₹321.00

Intrinsic Value of Biocon Ltd as of February 24, 2025 is: 379.42

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 24, 2025, Biocon Ltd is Undervalued by 18.20% compared to the current share price ₹321.00

Last 5 Year EPS CAGR: 9.89%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (8,142.46 cr) compared to borrowings (5,778.77 cr), indicating strong financial stability. The company has shown consistent growth in sales (5.38 cr) and profit (481.46 cr) over the years.	The stock has a low average ROCE of 10.58%, which may not be favorable. The stock has a high average Working Capital Days of 34.83, which may not be favorable. The stock has a high average Cash Conversion Cycle of 91.42, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biocon Ltd:
1. Net Profit Margin: 9.36%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 6.37% (Industry Average ROCE: 16.05%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 5.16% (Industry Average ROE: 15.89%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 2.43
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.66
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 46.9 (Industry average Stock P/E: 34.53)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.79
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 2127.30 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	20th K.M. Hosur Road, Bengaluru Karnataka 560100	investor.relations@biocon.com http://www.biocon.com

Management
Name	Position Held
Ms. Kiran Mazumdar Shaw	Executive Chairperson
Mr. Siddharth Mittal	Managing Director & CEO
Prof. Ravi Rasendra Mazumdar	Non Exe.Non Ind.Director
Mr. Eric Vivek Mazumdar	Non Exe.Non Ind.Director
Mr. Meleveetil Damodaran	Lead Independent Director
Dr. Vijay Kumar Kuchroo	Independent Director
Mr. Bobby Kanubhai Parikh	Independent Director
Mr. Peter John Bains	Independent Director
Mr. Naina Lal Kidwai	Independent Director

FAQ

What is the latest intrinsic value of Biocon Ltd?

Let's break down Biocon Ltd's intrinsic value simply:

We calculate intrinsic value using the PE Ratio Method - comparing the company's current price-to-earnings ratio with its historical average and industry peers. Think of it like checking if a stock is "on sale" compared to its typical pricing.

As of 24 February 2025:

Calculated Fair Value: ₹345.27
Current Market Price: ₹321.00
Variance: 7.56% higher

This suggests Biocon Ltd is currently undervalued by 7.56%. For context:

Market Cap: 38,605 Cr.
52-Week Range: 405/244
Reserves (Sep 2024): ₹20,393 Cr
Liabilities: 57,128 Cr

Remember: The PE method gives a snapshot based on earnings multiples. While useful for quick comparisons, investors should also consider growth prospects, industry trends, and economic conditions. This calculation assumes historical PE ratios remain relevant - always verify with current market dynamics.

What is the Market Cap of Biocon Ltd?

The Market Cap of Biocon Ltd is 38,605 Cr..

What is the current Stock Price of Biocon Ltd as on 24 February 2025?

The current stock price of Biocon Ltd as on 24 February 2025 is ₹321.

What is the High / Low of Biocon Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Biocon Ltd stocks is 405/244.

What is the Stock P/E of Biocon Ltd?

The Stock P/E of Biocon Ltd is 46.9.

What is the Book Value of Biocon Ltd?

The Book Value of Biocon Ltd is 175.

What is the Dividend Yield of Biocon Ltd?

The Dividend Yield of Biocon Ltd is 0.16 %.

What is the ROCE of Biocon Ltd?

The ROCE of Biocon Ltd is 5.96 %.

What is the ROE of Biocon Ltd?

The ROE of Biocon Ltd is 5.25 %.

What is the Face Value of Biocon Ltd?

The Face Value of Biocon Ltd is 5.00.